Literature DB >> 10618001

Therapeutic effects of docosahexaenoic acid ethyl ester in patients with generalized peroxisomal disorders.

M Martínez1, E Vázquez, M T García-Silva, J Manzanares, J M Bertran, F Castelló, I Mougan.   

Abstract

Generalized peroxisomal disorders are severe congenital diseases that involve the central nervous system, leading to severe psychomotor retardation, retinopathy, liver disease, and early death. In these disorders, peroxisomes are not normally formed and their enzymes are deficient. Characteristically, plasmalogen synthesis and beta-oxidation of very-long-chain fatty acids (VLCFAs) are affected. We found that patients with generalized peroxisomal disorders have a profound brain deficiency of docosahexaenoic acid (DHA; 22:6n-3) and low DHA concentrations in all tissues and the blood. Given the fundamental role of DHA in neuronal and retinal membranes, a DHA deficiency of this magnitude might be pathogenic. Thus, we studied the possible therapeutic effect of normalizing DHA concentrations in patients with peroxisomal disorders. We chose the DHA ethyl ester (DHA-EE) because of its high degree of purity at daily oral doses of 100-500 mg. This article summarizes the results of treatment of 13 patients with DHA-EE, with some follow-up evidence of clinical improvement. Supplementation with DHA-EE normalized blood DHA values within a few weeks. Plasmalogen concentrations increased in erythrocytes in most patients and after DHA concentrations were normalized, amounts of VLCFAs decreased in plasma. Liver enzymes returned almost to normal in most cases. From a clinical viewpoint, most patients showed improvement in vision, liver function, muscle tone, and social contact. In 3 patients, normalization of brain myelin was detected by magnetic resonance imaging. In 3 others, myelination improved. In a seventh patient, myelination is progressing at a normal rate. These results suggest a fundamental role of DHA in the pathogenesis of Zellweger syndrome. DHA therapy is thus strongly recommended, not only to alleviate symptoms in patients with life-threatening diseases, but also to clarify remaining questions regarding the role of DHA in health and disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10618001     DOI: 10.1093/ajcn/71.1.376s

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  19 in total

1.  Phosphatidylserine-dependent neuroprotective signaling promoted by docosahexaenoic acid.

Authors:  Hee-Yong Kim; Mohammed Akbar; Yang-Suk Kim
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2010-03-05       Impact factor: 4.006

2.  Omega-3 fatty acids improve recovery, whereas omega-6 fatty acids worsen outcome, after spinal cord injury in the adult rat.

Authors:  Von R King; Wenlong L Huang; Simon C Dyall; Olimpia E Curran; John V Priestley; Adina T Michael-Titus
Journal:  J Neurosci       Date:  2006-04-26       Impact factor: 6.167

3.  Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival.

Authors:  Mohammed Akbar; Frances Calderon; Zhiming Wen; Hee-Yong Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-22       Impact factor: 11.205

Review 4.  Plasmalogens, phospholipase A2, and docosahexaenoic acid turnover in brain tissue.

Authors:  A A Farooqui; L A Horrocks
Journal:  J Mol Neurosci       Date:  2001 Apr-Jun       Impact factor: 3.444

Review 5.  Docosahexaenoic acid accumulation in the prenatal brain: prooxidant and antioxidant features.

Authors:  E Yavin; S Glozman; P Green
Journal:  J Mol Neurosci       Date:  2001 Apr-Jun       Impact factor: 3.444

Review 6.  Restoring the DHA levels in the brains of Zellweger patients.

Authors:  M Martinez
Journal:  J Mol Neurosci       Date:  2001 Apr-Jun       Impact factor: 3.444

Review 7.  Biochemical and biological functions of docosahexaenoic acid in the nervous system: modulation by ethanol.

Authors:  Hee-Yong Kim
Journal:  Chem Phys Lipids       Date:  2008-03-02       Impact factor: 3.329

Review 8.  Mechanisms of disease: Inborn errors of bile acid synthesis.

Authors:  Shikha S Sundaram; Kevin E Bove; Mark A Lovell; Ronald J Sokol
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-06-24

Review 9.  Neurological benefits of omega-3 fatty acids.

Authors:  S C Dyall; A T Michael-Titus
Journal:  Neuromolecular Med       Date:  2008-06-10       Impact factor: 3.843

10.  Circulating plasmalogen levels and Alzheimer Disease Assessment Scale-Cognitive scores in Alzheimer patients.

Authors:  Paul L Wood; Rishikesh Mankidy; Shawn Ritchie; Doug Heath; Julie A Wood; John Flax; Dayan B Goodenowe
Journal:  J Psychiatry Neurosci       Date:  2010-01       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.